NCT06622486View on ClinicalTrials.gov

First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 27, 2024

Primary Completion Date

January 23, 2027

Study Completion Date

January 23, 2027

Conditions
Solid Tumor, Adult
Interventions
DRUG

EGL-001

IV administration

Trial Locations (8)

Unknown

NOT_YET_RECRUITING

Centr Georges Francois Leclerc, Dijon

RECRUITING

Institut Regional Du Cancer De Montpellier, Montpellier

RECRUITING

Institut Curie, Paris

NOT_YET_RECRUITING

Institut Gustave Roussy, Paris

NOT_YET_RECRUITING

Hospital Universitari Vall D Hebron, Barcelona

NOT_YET_RECRUITING

Hospital Universitario Fundacion Jimenez Diaz, Madrid

NOT_YET_RECRUITING

Clinica Universidad De Navarra, Pamplona

RECRUITING

Hospital Clinico Universitario De Valencia, Valencia

Sponsors

Lead Sponsor

Egle Therapeutics
All Listed Sponsors
lead

Egle Therapeutics

INDUSTRY

NCT06622486 - First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter